The most widely studied radioconjugates for the treatment of B-cell non-Hodgkin’s lymphoma (NHL) are murine anti-CD20 mAbs radiolabelled with 131I (tositumomab, Bexxar®; GlaxoSmithKline, Brentford, UK; no longer available) or with the pure β-emitting isotope 90Y (ibritumomab tiuxetan, Zevalin®; Spectrum Pharmaceuticals Inc., Henderson, NV). This evidence concerns the gene MS4A1 and B-cell non-Hodgkin lymphoma.